Methotrexate plus etanercept for juvenile arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study compares methotrexate alone versus methotrexate combined with etanercept to see which works better for children with polyarticular juvenile idiopathic arthritis. The goal is to help children achieve low disease activity quickly.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 2 and 16 years old.
- Your child must have a type of JIA called polyarticular JIA.
- Your child should be newly diagnosed and not have taken methotrexate or etanercept before.
- Your child cannot have a serious infection or have needed hospital care for an infection in the past month.
- Your child must not have active tuberculosis, hepatitis B, or any other ongoing infection.
- Your child must not have a history of cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether children with juvenile idiopathic arthritis (JIA) who have been doing well for over a year can safely reduce their medications. The goal is to find the best way to keep arthritis under control while avoiding unnecessary treatments.
This study tests a methotrexate injection (given under the skin) for people with moderate to severe rheumatoid arthritis who haven't taken methotrexate before. Researchers want to see how the medicine builds up in your body and if it helps control your symptoms.
This Phase 3 study tests whether children with early juvenile idiopathic arthritis do better by starting with one treatment approach and adjusting (stepping up or stepping down) based on how their arthritis responds. It may help find the safest, most effective long-term plan for controlling symptoms with fewer side effects.
This study compares two combination treatments for rheumatoid arthritis in people whose current methotrexate or leflunomide isn’t working well enough. It aims to see whether adding a targeted therapy works better than the standard add-on of sulfasalazine plus hydroxychloroquine.
This trial tests whether increasing your methotrexate dose or switching from pills to injections can better control active rheumatoid arthritis. It's for people already taking a stable, moderate dose of methotrexate but still having joint swelling and symptoms.
This trial tests if a treatment can prevent joint damage in people recently diagnosed with psoriatic arthritis. It compares a standard medication (methotrexate) with or without a newer biologic drug (adalimumab) to see which is better at stopping the disease from causing lasting harm.
Hear when a new Juvenile Idiopathic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.